(ANAB) AnaptysBio - Overview

Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 1.650m USD | Total Return: 198.3% in 12m

Stock Antibodies, Therapeutics, Immunology, Inflammation
Total Rating 69
Risk 36
Buy Signal -0.42
Biotechnology +0.2
Biotechnology +1.0
Market Cap: 1,650m
Avg Trading Vol: 41.3M USD
ATR: 7.60%
Peers RS (IBD): 81.8
Risk 5d forecast
Volatility74.0%
Rel. Tail Risk-20.5%
Reward TTM
Sharpe Ratio1.89
Alpha183.01
Character TTM
Beta0.383
Beta Downside0.177
Drawdowns 3y
Max DD69.32%
CAGR/Max DD0.54
EPS (Earnings per Share) EPS (Earnings per Share) of ANAB over the last years for every Quarter: "2021-03": -0.66, "2021-06": -0.02, "2021-09": -0.24, "2021-12": -1.13, "2022-03": -1.31, "2022-06": -1.15, "2022-09": -1.18, "2022-12": -0.93, "2023-03": -1.58, "2023-06": -1.5, "2023-09": -1.41, "2023-12": -1.59, "2024-03": -1.64, "2024-06": -1.71, "2024-09": -1.14, "2024-12": -0.72, "2025-03": -1.28, "2025-06": -1.34, "2025-09": 0.52, "2025-12": 1.58, "2026-03": 0,
EPS CAGR: 29.86%
EPS Trend: 61.6%
Last SUE: 1.37
Qual. Beats: 3
Revenue Revenue of ANAB over the last years for every Quarter: 2021-03: 11.247, 2021-06: 30.027, 2021-09: 20.89, 2021-12: 1.010999, 2022-03: 0.97, 2022-06: 1.216, 2022-09: 1.293, 2022-12: 6.808, 2023-03: 1.374, 2023-06: 3.46, 2023-09: 3.318, 2023-12: 9.005, 2024-03: 7.179, 2024-06: 10.971, 2024-09: 30.017, 2024-12: 43.113, 2025-03: 27.771, 2025-06: 22.263, 2025-09: 76.32, 2025-12: 108.249, 2026-03: null,
Rev. CAGR: 251.59%
Rev. Trend: 94.7%
Last SUE: 1.40
Qual. Beats: 2
Risks
Technicals: volatile
Description: ANAB AnaptysBio March 04, 2026

AnaptysBio Inc. is a clinical-stage biotechnology company developing immunology therapeutics. The companys business model centers on advancing antibody programs through preclinical and clinical phases, often through collaborations.

Key product candidates include Rosnilimab, targeting PD-1+ T cells for autoimmune diseases; ANB032, an antibody for the BTLA checkpoint receptor; and Imsidolimab, in Phase 3 development for generalized pustular psoriasis. The biotechnology sector is characterized by lengthy and capital-intensive drug development cycles.

AnaptysBio has a collaboration and license agreement with GlaxoSmithKline, Inc. Further research on ValueRay can provide detailed financial and operational data.

Headlines to Watch Out For
  • Clinical trial results for lead drug candidates impact stock.
  • Regulatory approval decisions for new therapies drive valuation.
  • Collaboration revenue from GSK partnership affects financials.
  • Research and development expenses influence profitability.
  • Competition from other immunology therapeutics impacts market share.
Piotroski VR‑10 (Strict, 0-10) 4.0
Net Income: -13.2m TTM > 0 and > 6% of Revenue
FCF/TA: 0.05 > 0.02 and ΔFCF/TA 33.43 > 1.0
NWC/Revenue: 132.8% < 20% (prev 423.4%; Δ -290.5% < -1%)
CFO/TA 0.05 > 3% & CFO 19.7m > Net Income -13.2m
Net Debt (52.4m) to EBITDA (66.7m): 0.79 < 3
Current Ratio: 9.07 > 1.5 & < 3
Outstanding Shares: last quarter (31.3m) vs 12m ago 2.94% < -2%
Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin)
Asset Turnover: 55.32% > 50% (prev 18.87%; Δ 36.45% > 0%)
Interest Coverage Ratio: 0.81 > 6 (EBITDA TTM 66.7m / Interest Expense TTM 79.9m)
Altman Z'' -2.76
A: 0.86 (Total Current Assets 350.2m - Total Current Liabilities 38.6m) / Total Assets 364.4m
B: -2.12 (Retained Earnings -772.6m / Total Assets 364.4m)
C: 0.15 (EBIT TTM 64.3m / Avg Total Assets 424.1m)
D: -2.36 (Book Value of Equity -772.6m / Total Liabilities 327.2m)
Altman-Z'' Score: -2.76 = D
Beneish M -3.14
DSRI: 0.32 (Receivables 33.9m/40.8m, Revenue 234.6m/91.3m)
GMI: 1.00 (fallback, negative margins)
AQI: 0.01 (AQ_t 0.00 / AQ_t-1 0.07)
SGI: 2.57 (Revenue 234.6m / 91.3m)
TATA: -0.09 (NI -13.2m - CFO 19.7m) / TA 364.4m)
Beneish M-Score: -3.14 (Cap -4..+1) = AA
What is the price of ANAB shares? As of April 01, 2026, the stock is trading at USD 55.46 with a total of 803,591 shares traded.
Over the past week, the price has changed by -12.00%, over one month by +1.00%, over three months by +14.40% and over the past year by +198.33%.
Is ANAB a buy, sell or hold? AnaptysBio has received a consensus analysts rating of 4.42. Therefore, it is recommended to buy ANAB.
  • StrongBuy: 7
  • Buy: 3
  • Hold: 2
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the ANAB price?
ISSUER TARGET UP/DOWN
Wallstreet Target Price 78.3 41.1%
Analysts Target Price 78.3 41.1%
ANAB Fundamental Data Overview March 31, 2026
P/S = 7.0338
P/B = 48.2563
Revenue TTM = 234.6m USD
EBIT TTM = 64.3m USD
EBITDA TTM = 66.7m USD
Long Term Debt = 14.1m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 2.08m USD (from shortTermDebt, last quarter)
Debt = 290.6m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 52.4m USD (from netDebt column, last quarter)
Enterprise Value = 1.63b USD (1.65b + Debt 290.6m - CCE 311.6m)
Interest Coverage Ratio = 0.81 (Ebit TTM 64.3m / Interest Expense TTM 79.9m)
EV/FCF = 83.08x (Enterprise Value 1.63b / FCF TTM 19.6m)
FCF Yield = 1.20% (FCF TTM 19.6m / Enterprise Value 1.63b)
FCF Margin = 8.36% (FCF TTM 19.6m / Revenue TTM 234.6m)
Net Margin = -5.64% (Net Income TTM -13.2m / Revenue TTM 234.6m)
 Gross Margin = unknown ((Revenue TTM 234.6m - Cost of Revenue TTM 2.42m) / Revenue TTM)
 Tobins Q-Ratio = 4.47 (Enterprise Value 1.63b / Total Assets 364.4m)
Interest Expense / Debt = 6.78% (Interest Expense 19.7m / Debt 290.6m)
Taxrate = 0.16% (81.0k / 49.7m)
NOPAT = 64.2m (EBIT 64.3m * (1 - 0.16%))
Current Ratio = 9.07 (Total Current Assets 350.2m / Total Current Liabilities 38.6m)
Debt / Equity = 7.81 (Debt 290.6m / totalStockholderEquity, last quarter 37.2m)
Debt / EBITDA = 0.79 (Net Debt 52.4m / EBITDA 66.7m)
Debt / FCF = 2.67 (Net Debt 52.4m / FCF TTM 19.6m)
Total Stockholder Equity = -730k (last 4 quarters mean from totalStockholderEquity)
RoA = -3.12% (Net Income -13.2m / Total Assets 364.4m)
 RoE = 1.81k% (out of range, set to none) (Net Income TTM -13.2m / Total Stockholder Equity -730k)
 RoCE = 480.6% (EBIT 64.3m / Capital Employed (Equity -730k + L.T.Debt 14.1m))
RoIC = 172.6% (NOPAT 64.2m / Invested Capital 37.2m)
WACC = 7.25% (E(1.65b)/V(1.94b) * Re(7.33%) + D(290.6m)/V(1.94b) * Rd(6.78%) * (1-Tc(0.00)))
Discount Rate = 7.33% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.92%
Shares Correlation 3-Years: 100.0 | Cagr: 8.58%
[DCF] Terminal Value 82.48% ; FCFF base≈19.6m ; Y1≈21.5m ; Y5≈27.5m
[DCF] Fair Price = 18.00 (EV 569.8m - Net Debt 52.4m = Equity 517.3m / Shares 28.7m; r=7.25% [WACC]; 5y FCF grow 11.13% → 3.0% )
EPS Correlation: 61.56 | EPS CAGR: 29.86% | SUE: 1.37 | # QB: 3
Revenue Correlation: 94.71 | Revenue CAGR: 251.6% | SUE: 1.40 | # QB: 2
EPS next Quarter (2026-06-30): EPS=-0.88 | Chg7d=-0.001 | Chg30d=+0.156 | Revisions Net=+3 | Analysts=9
EPS current Year (2026-12-31): EPS=-4.02 | Chg7d=-0.012 | Chg30d=+0.081 | Revisions Net=+4 | Growth EPS=-773.8% | Growth Revenue=-52.6%
EPS next Year (2027-12-31): EPS=-4.05 | Chg7d=-0.689 | Chg30d=+0.633 | Revisions Net=+1 | Growth EPS=-0.9% | Growth Revenue=+41.2%
[Analyst] Revisions Ratio: +0.60 (4 Up / 1 Down within 30d for Next Quarter)
Additional Sources for ANAB Stock Fund Manager Positions: Dataroma · Stockcircle